Viking Therapeutics (1VT) Stock Price & Analysis
1VT Stock Chart & Stats
- Day’s Range
- EUR 24.00 - EUR 24.55
- 52-Week Range
- EUR 21.60 - EUR 40.00
- Previous Close
- EUR 24.25
- Volume
- N/A
- Average Volume (3M)
- 873
- Market Cap
- EUR 3.11B
- Enterprise Value
- EUR 3.14B
- Total Cash (Recent Filing)
- EUR 959.81M
- Total Debt (Recent Filing)
- EUR 254.69M
- Price to Earnings (P/E)
- ―
- Beta
- 0.87
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -1.23
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Progress
Advancing both injectable and oral VK2735 programs into late-stage trials strengthens Viking’s development platform and expands potential product formats. Fully enrolled studies and a new registration program create multiple upcoming clinical milestones that could support future commercialization if results and regulatory reviews are favorable.
Efficacy And Flexible Dosing
Sustained weight loss with every-other-week and monthly regimens could differentiate VK2735 beyond initial efficacy by addressing long-term maintenance and dosing convenience. These findings support a broader product profile, although confirmation in later-stage studies remains necessary before they can underpin an approved label.
Funding Runway
The strengthened cash position gives Viking substantial resources to continue expensive Phase III development, advance VK3019, and build commercial capabilities without relying immediately on another financing. That liquidity supports execution over the next several quarters, though ongoing spending will determine how long the runway lasts.
Bears Say
No Commercial Revenue And Widening Losses
Viking has not yet established a commercial revenue stream to offset research and operating costs, leaving its financial outlook dependent on clinical progress and future product approval. Rapidly widening losses increase the amount of capital required before the business can potentially become self-funding.
Heavy Cash Burn
Large and deteriorating cash outflows make continued financing capacity central to Viking’s ability to complete development programs and prepare for launch. Persistent burn can reduce strategic flexibility and increase future equity or debt needs, even though the recent financing temporarily improves available liquidity.
Rising Leverage
The move from minimal historical debt to $255 million adds fixed financial obligations to a company that is still loss-making and cash-consuming. Higher leverage can narrow flexibility during clinical delays or regulatory setbacks and may compete with research and commercialization spending for future capital.
Viking Therapeutics News
1VT FAQ
What was Viking Therapeutics’s price range in the past 12 months?
What is Viking Therapeutics’s market cap?
When is Viking Therapeutics’s upcoming earnings report date?
How were Viking Therapeutics’s earnings last quarter?
Is Viking Therapeutics overvalued?
Does Viking Therapeutics pay dividends?
What is Viking Therapeutics’s EPS estimate?
How many shares outstanding does Viking Therapeutics have?
What happened to Viking Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Viking Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Viking Therapeutics Stock Smart Score
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Lian
- Employees
- 65
- Website
- www.vikingtherapeutics.com
- Address
- 9920 Pacific Heights Boulevard, San Diego, CA, 92121, US
Viking Therapeutics (1VT) Earnings & Revenues
1VT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive on clinical and operational progress. Viking reported fully enrolled and on-track subcutaneous Phase III studies, initiation of the oral Phase III program, encouraging efficacy and tolerability results from VK2735 maintenance studies, advancement of VK3019, and a substantially strengthened cash position. The main negative factors were sharply higher operating expenses, a substantially wider net loss, ongoing cash usage of around $100 million per quarter, and uncertainty around future maintenance-study and regulatory outcomes. Highlights significantly outweighed lowlights.
View all DE:1VT earnings summaries1VT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 4 | 11 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 5 | 0 | 7 |
